Natixis Advisors LLC Acquires 44,646 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Natixis Advisors LLC lifted its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 16.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 320,013 shares of the company’s stock after purchasing an additional 44,646 shares during the period. Natixis Advisors LLC owned about 0.35% of Myriad Genetics worth $8,765,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in MYGN. UniSuper Management Pty Ltd bought a new stake in Myriad Genetics in the 1st quarter worth $467,000. State of New Jersey Common Pension Fund D bought a new stake in Myriad Genetics in the 3rd quarter worth $1,965,000. Legato Capital Management LLC bought a new stake in Myriad Genetics in the 2nd quarter worth $1,123,000. Assenagon Asset Management S.A. grew its holdings in Myriad Genetics by 26.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 250,524 shares of the company’s stock worth $6,128,000 after acquiring an additional 52,813 shares during the last quarter. Finally, Maven Securities LTD bought a new stake in Myriad Genetics in the 2nd quarter worth $1,223,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Paul J. Diaz sold 15,000 shares of the company’s stock in a transaction on Friday, October 11th. The stock was sold at an average price of $22.93, for a total value of $343,950.00. Following the completion of the sale, the chief executive officer now directly owns 962,378 shares in the company, valued at $22,067,327.54. This represents a 1.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Colleen F. Reitan sold 46,012 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total value of $1,286,035.40. Following the completion of the transaction, the director now directly owns 42,533 shares in the company, valued at $1,188,797.35. This trade represents a 51.96 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,012 shares of company stock valued at $1,900,485. Insiders own 2.10% of the company’s stock.

Myriad Genetics Trading Down 1.2 %

NASDAQ:MYGN opened at $15.12 on Friday. Myriad Genetics, Inc. has a one year low of $14.72 and a one year high of $29.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The company’s 50-day simple moving average is $22.50 and its 200 day simple moving average is $24.48. The firm has a market capitalization of $1.38 billion, a P/E ratio of -11.63 and a beta of 1.93.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MYGN. Piper Sandler cut their price target on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating on the stock in a report on Monday, November 11th. Scotiabank lifted their target price on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research note on Tuesday, August 13th. StockNews.com lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Wednesday. Wells Fargo & Company began coverage on shares of Myriad Genetics in a research note on Tuesday, August 27th. They set an “overweight” rating and a $35.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their target price on shares of Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Myriad Genetics has an average rating of “Hold” and an average target price of $27.36.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.